REFERENCES
1. Ferlay, J., et al., Estimating the global cancer incidence and
mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019.144 (8): p. 1941-1953.
2. Strongman, H., et al., Medium and long-term risks of specific
cardiovascular diseases in survivors of 20 adult cancers: a
population-based cohort study using multiple linked UK electronic health
records databases. Lancet, 2019. 394 (10203): p. 1041-1054.
3. Koene, R.J., et al., Shared Risk Factors in Cardiovascular
Disease and Cancer. Circulation, 2016. 133 (11): p. 1104-14.
4. Curigliano, G., et al., Cardiotoxicity of anticancer
treatments: Epidemiology, detection, and management. CA Cancer J Clin,
2016. 66 (4): p. 309-25.
5. Cardinale, D., et al., Anthracycline-induced cardiomyopathy:
clinical relevance and response to pharmacologic therapy. J Am Coll
Cardiol, 2010. 55 (3): p. 213-20.
6. Romond, E.H., et al., Seven-year follow-up assessment of
cardiac function in NSABP B-31, a randomized trial comparing doxorubicin
and cyclophosphamide followed by paclitaxel (ACP) with ACP plus
trastuzumab as adjuvant therapy for patients with node-positive, human
epidermal growth factor receptor 2-positive breast cancer. J Clin
Oncol, 2012. 30 (31): p. 3792-9.
7. Florescu, M., et al., Early detection of epirubicin-induced
cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr,
2014. 27 (1): p. 83-92.
8. Negishi, K., et al., Independent and incremental value of
deformation indices for prediction of trastuzumab-induced
cardiotoxicity. J Am Soc Echocardiogr, 2013. 26 (5): p. 493-8.
9. Zamorano, J.L., et al., 2016 ESC Position Paper on cancer
treatments and cardiovascular toxicity developed under the auspices of
the ESC Committee for Practice Guidelines: The Task Force for cancer
treatments and cardiovascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J, 2016. 37 (36): p. 2768-2801.
10. Zornoff, L.A., et al., Right ventricular dysfunction and risk
of heart failure and mortality after myocardial infarction. J Am Coll
Cardiol, 2002. 39 (9): p. 1450-5.
11. Larose, E., et al., Right ventricular dysfunction assessed by
cardiovascular magnetic resonance imaging predicts poor prognosis late
after myocardial infarction. J Am Coll Cardiol, 2007. 49 (8):
p. 855-62.
12. Motoki, H., et al., Right ventricular global longitudinal
strain provides prognostic value incremental to left ventricular
ejection fraction in patients with heart failure. J Am Soc
Echocardiogr, 2014. 27 (7): p. 726-32.
13. Ylanen, K., et al., Cardiac magnetic resonance imaging in the
evaluation of the late effects of anthracyclines among long-term
survivors of childhood cancer. J Am Coll Cardiol, 2013.61 (14): p. 1539-47.
14. Medvedofsky, D., et al., Novel Approach to Three-Dimensional
Echocardiographic Quantification of Right Ventricular Volumes and
Function from Focused Views. J Am Soc Echocardiogr, 2015.28 (10): p. 1222-31.
15. Nagata, Y., et al., Prognostic Value of Right Ventricular
Ejection Fraction Assessed by Transthoracic 3D Echocardiography. Circ
Cardiovasc Imaging, 2017. 10 (2).
16. Grapsa, J., et al., Right ventricular remodelling in pulmonary
arterial hypertension with three-dimensional echocardiography:
comparison with cardiac magnetic resonance imaging. Eur J Echocardiogr,
2010. 11 (1): p. 64-73.
17. Muraru, D., et al., New speckle-tracking algorithm for right
ventricular volume analysis from three-dimensional echocardiographic
data sets: validation with cardiac magnetic resonance and comparison
with the previous analysis tool. Eur Heart J Cardiovasc Imaging, 2016.17 (11): p. 1279-1289.
18. Zhao, R., et al., Early Detection and Prediction of
Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional
Echocardiography. JACC: CardioOncology, 2020. 2 (1): p. 13-22.
19. Rudski, L.G., et al., Guidelines for the echocardiographic
assessment of the right heart in adults: a report from the American
Society of Echocardiography endorsed by the European Association of
Echocardiography, a registered branch of the European Society of
Cardiology, and the Canadian Society of Echocardiography. J Am Soc
Echocardiogr, 2010. 23 (7): p. 685-713; quiz 786-8.
20. Kang, Y., et al., Two-dimensional speckle tracking
echocardiography combined with high-sensitive cardiac troponin T in
early detection and prediction of cardiotoxicity during
epirubicine-based chemotherapy. Eur J Heart Fail, 2014. 16 (3):
p. 300-8.
21. Khouri, M.G., et al., Utility of 3-dimensional
echocardiography, global longitudinal strain, and exercise stress
echocardiography to detect cardiac dysfunction in breast cancer patients
treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res
Treat, 2014. 143 (3): p. 531-9.
22. Narayan, H.K., et al., Detailed Echocardiographic Phenotyping
in Breast Cancer Patients: Associations With Ejection Fraction Decline,
Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.Circulation, 2017. 135 (15): p. 1397-1412.
23. Swain, S.M., F.S. Whaley, and M.S. Ewer, Congestive heart
failure in patients treated with doxorubicin: a retrospective analysis
of three trials. Cancer, 2003. 97 (11): p. 2869-79.
24. Stopeck, A.T., et al., A phase 2 trial of standard-dose
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and
rituximab plus bevacizumab for patients with newly diagnosed diffuse
large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood, 2012.120 (6): p. 1210-7.
25. Goldberg, M.A., et al., Cyclophosphamide cardiotoxicity: an
analysis of dosing as a risk factor. Blood, 1986. 68 (5): p.
1114-8.
26. Ho, E., et al., Subclinical anthracycline- and
trastuzumab-induced cardiotoxicity in the long-term follow-up of
asymptomatic breast cancer survivors: a speckle tracking
echocardiographic study. Heart, 2010. 96 (9): p. 701-7.
27. Thavendiranathan, P., et al., Reproducibility of
echocardiographic techniques for sequential assessment of left
ventricular ejection fraction and volumes: application to patients
undergoing cancer chemotherapy. J Am Coll Cardiol, 2013.61 (1): p. 77-84.
28. Perel, R.D., R.E. Slaughter, and W.E. Strugnell,Subendocardial late gadolinium enhancement in two patients with
anthracycline cardiotoxicity following treatment for Ewing’s sarcoma. J
Cardiovasc Magn Reson, 2006. 8 (6): p. 789-91.
29. Thavendiranathan, P., et al., Use of myocardial strain imaging
by echocardiography for the early detection of cardiotoxicity in
patients during and after cancer chemotherapy: a systematic review. J
Am Coll Cardiol, 2014. 63 (25 Pt A): p. 2751-68.
30. Smiseth, O.A., et al., Myocardial strain imaging: how useful
is it in clinical decision making? Eur Heart J, 2016. 37 (15):
p. 1196-207.
31. Simon, M.A., Assessment and treatment of right ventricular
failure. Nat Rev Cardiol, 2013. 10 (4): p. 204-18.
32. Gulati, A., et al., The prevalence and prognostic significance
of right ventricular systolic dysfunction in nonischemic dilated
cardiomyopathy. Circulation, 2013. 128 (15): p. 1623-33.
33. Christiansen, J.R., et al., Right ventricular function in
long-term adult survivors of childhood lymphoma and acute lymphoblastic
leukaemia. Eur Heart J Cardiovasc Imaging, 2016. 17 (7): p.
735-41.
34. Kocabas, A., et al., Assessment of early-onset chronic
progressive anthracycline cardiotoxicity in children: different response
patterns of right and left ventricles. Pediatr Cardiol, 2014.35 (1): p. 82-8.
35. Skali, H., et al., Prognostic use of echocardiography 1 year
after a myocardial infarction. Am Heart J, 2005. 150 (4): p.
743-9.
Figure Legends
Figure 1: Flowchart detailing patient selection.
Figure 2: ROC curves for 3D Echocardiographic Parameters in Predicting
Later CAEs. (A) ROC curve analysis of LVGLS and RVEF respectively. The
area under the curve (AUC) of LVGLS was 0.787 (95% CI, 0.666-0.908; P
< .0001) (blue line) and the AUC of RVEF was 0.811 (95% CI,
0.712-0.910; P < .0001) (green line). (B) ROC curve analysis
of combined LVGLS and RVEF (curve). When LVGLS and RVEF were combined in
the ROC curve analysis, the sensitivity increased to 88.9%, the
specificity was 82.1%, and the AUC increased to 0.882.
Figure 3: CAEs-free survival according to RVEF. Kaplan-Meier curves
depicting CAEs-free survival in patients with RVEF above or below the
absolute value of 46.33 %. Patients. *P =0.007.
Figure 4: Stepwise addition of left ventricular RVEF to GLS. On
multivariate stepwise block analysis, adding RVEF to GLS gives
significant additional prognostic value.
Figure 1